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Objectives. This study assessed the efficacy of the combination 
of sotalol and either quinidine or procainamide in preventing 
sustained ventricular tachycardia inducibility and recurrence and 
prospectiwely evaluated the ability of the drug combination to 
prevent ventricular tachycardia recurrence when the arrhythmia 
remained ifflducible but was moditied. 
Buckground. Individual antiarrhythmi~ drugs are often inef- 
fective in preventing the induction and recurrence of sustained 
ventricular tacbycardia. eta-adrenergic blochade and pro:onga- 
tion of refractoriness may be importaut components of successful 
antiarrhythmic therapy in patients with ventricular tachycardia. 
We reasoned that the combination of sotatol, which has beta- 
adrenergic blocking properties and prolongs ventricular refracto- 
riness, and quinidine or procainamide, two agents that slow 
conduction and prolong refractory periods, would be effective 
therapy in such patients. 
Methods. We administered low dose sotalol(205 + 84 mg/day) 
plus quinidine sulfate (1,278 f 479 mgkday) or procainamide 
(2,393 * 1,423 mg/day) to 50 patients with spontaneous sustained 
ventricular tachycardia or fibrillation and inducible ventricular 
tachyrardia. 
Results. In 21 (46%) of 46 patients, ventricular taehycardia 
was rendered noninducible at electrophysiologic study (group I), 
and in 17 patients (37%), inducible ~cbycardia was iodized 
according to prospectively identified criteria (group II), for a 
Despite recent progress in the understanding of the pdtho- 
physiology of sustained ventricular tachycardia and im- 
provements in its management, there remains agreat need 
for effective and safe pharmacotherapy in patients with 
sustained ventricular tachycardia or fibrillation. 
It is generally accepted that among patients with sponta- 
neous ustained ventricular tachycardia and inducible sus- 
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patients in groups I au 
KG 5o~tot plus ~ota~dtne or 
ventrtcular refractoriness and 
patients. Patients with 
a low rate of arrhyt 
co~~binatioa deserves 
re~ar~e~ce in follow-up. 
tained ventricular tachycardia at drug-free lectrophysio- 
logic study, the inability to induce sustained ventricular 
tachycardia in the presence ofan antiarrhythmic drug con- 
fers a low likelihood (< H%/year) of spontaneous tachycar- 
dia recurrence (l-3). However, the overall chance of drug 
“success” at electrophysiologic study is only 10% to 40%. 
depending on the drug, the study patients and the number of 
agents tested (4). Conversely, it has been suggested that he 
continued ability to induce ventricular tachycardia despite 
the presence of an antiarrhythmic drug confers a high 
probability ofarrhythmia recurrence (50% to 80% at I year) 
(3), although insome retrospective studies (1,5,6), a possible 
benefit from drugs that slow induced ventricular tachycardia 
but do not prevent i s inducibihty has been observed. 
Lack of efficacy and toxicity of individual gents have led 
many investigators (7-10) to assess antiarrhythmic drug 
combinations i  the therapy of sustained ventricular rhyth- 
0735-1097/93/$6.(H) 
than comductiom 
would be useful i 
drugs that slow cardiac 
tricular tachycardia remained ix% 
We therefore prospectively stud 
Ah patients referred to the cardia 
service at the Toronto Western and St. 
for the evaluation and treatment of documented or 
sustained ventricular tachycardia or ~bril~atio~ we 
for treatment with sotalol pl s procainamide or 
They included all patients who could undergo 
electrophysiologic study in the absence of 
medications, had ~~d~cib~c sustained mo~om 
ular tachycardia atbaseline study and had be 
at least one a~tia~hythm~c drug that fai!ed t 
tachycardia. Nopatient had a potentially 
reversible cause for ventricular tachycardia (myocardial 
infarction within the previous week, acute myocardial isch- 
emia, long QT interval, electrolyte disturbance or apparent 
drug-induced ventricular tachycardia. Patients with a defi- 
nite contraindication t  beta-blockade ( ocumented history 
of bronchospasm, previous documented a verse r actions to
beta-block.ers o  ongoing uncontrolled congestive heart fail- 
ure) were not eligible for study. Poor ventricular function in 
the absence of active congestive heart failure was not 
considered a contraindicatio.?. 
My consecutive patients who ~eceiv~~I treaimcr,C with 
sotalol plus quinidine or procamamide form the substance of 
this report. The study was approved by t man Subjects 
Review Committee ofToronto Western tal. 
atient ev2~~2ti~~~ Aii patients underwent 2 general med- 
ical and cardiac ‘evaluation. Baseline valuation i cluded 
continuous electrocardiographic (EC%) nonitoring and dis- 
continuation f all antiarrbythmic drugs for 25 half-lives. 
~2s measure y 
dine was adm~n~st~re~ 
three times daily) and 
release forrn~~at~0~ at 
month intervals. 
e standard efinitions for ven- 
Spontaneous or induced sLastaened ventricular ~achycardia 
= monoform ventricular tachycardia lasting 230 s or 
causing synco ete~o~~io~ requir- 
ing immediate t ~i~atio~. 
Indticible ventricular tachycardia = 2 15 repetitive ven- 
tricular esponses after programmed stimulation. 
Mod$ed ventricular tac~y~~rd~a i~zdl~cj~ili~ = induce 
ve~t~c~lar t chycardia meeting of 
pr0spectively defined criteria: 11 induced vent& 
tacbycardia cycle length ~50 ms longer than 
baseline induced tachycardia cycle I 
te~~~2tio~ f induced veat~c~~ar L 
possible; and 3) the induced ventricu 
was well tolerated with mild or no s 
presyncope or loss of conscioustress. A~tbougb in- 
?raarterial blood pressure was measured for all pa- 
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Table 1. Characteristics of 45 Study k&ntS 
..- 
Group I Group 2 Group 3 
(n = 21) (n = 17) 111 = 8) p Value 
Age (yr) 58.9 f 7.6 62.0 2 6.0 66.4 2 5.2 < 0.05 
CAD (%) Bi 9 inn 
5,” 
ii.? 
Male/female 1417 17lLL 810 < 0.01 
EF (%) 34 t I4 282 II 29 2 7 NS 
VTNF 1912 1314 711 NS 
No. of unsuccessful drugs 2.2 t i.4 2.6 f I.5 2.1 k I.1 NS 
Sotalol dose (mglday) 213 i: 77 198 2 98 200 2 74 NS 
Procainamide dose (mglday) 2,200 ” 447 2,731 + 2,411 2.200 + 1,131 NS 
Quinidine dose (mglday) 1,363 + 572 1,308 + 253 845 + 511 NS 
Data are expressed as mean value it SD or number or percent of patients. CAD = coronary artery disease: 
EF = ejection fraction; No. of unsuccessful drugs = number of drugs resulting in sponlaneous A; induced sustained 
ventricular tachycardia (VT) before combination drug therapy was given; VF = cardiac arrest with veatdcular 
fibrillation as the presenting arrhythmia. Group I = patients whose ventricular tachycardia was rendered 
noninducible by combination therapy with sotalol plus procainamide or quinidine; Group 2 = patients whose 
inducible tachycardia was modified by combination therapy; Group 3 = patients whose tachycardia was not modified 
by combination therapy. Note that 4 of the SO patients did not undergo posttreatment electrophysiologic study (see 
Risults section). 
tients, no specific blood pressure cutoff was included 
in the definition. 
Patients in whom ventricular tachycardia was tendered 
noninducible (group I , 22 15 repetitive ventricular responses) 
by the combination drdg therapy or in whom inducibility was 
modified (group II) were eligible for long-term treatment 
with the drug combination, Patients failing to meet either of 
these criteria (group III) were treated with other egimens. 
Statistical nalysis. Continuous variables were analyzed 
by means of t tests and analysis of variance (ANOVA). 
Intergroup differences were evaluated by Duncan’s multiple 
range test and linear egression. Categoric variables were 
analyzed with chi-square t sts. Curves for freedom from 
sudden death or arrhphmia recurrence were analyzed uslalg 
the Kaplan-Meier method and compared using the log-rank 
test; p values < 0.0.5 were considered significant. 
Study patients. There were 42 men and 8 women with an 
average age of 61.4 + 7.1 years (range 47 to 74). Forty-four 
had coronary artery disease with previous myocardial infarc- 
tion or documented bycoronary arteriography, or both, live 
had idiopathic dilated cardiomyopathy and one ha 
cwigktd heart disease. Forty-:wo patients had 8 history of 
documented sustained moriull, --_=rphic ventricular tachycar- 
dia, including 17 with a history of syncope; 7patients had a 
history of cardiac arrest and I patient bad syncope of 
unknown origin clinically thought to be due to ventricular 
tachycardia. 
ean ejection fraction by radionuclide angiography (49 
patients) or echocardiog pby (1 patient) was 31 rt 12% 
(range 10% to 73%), wi 17 patients having an ejection 
fraction 125%. Age and gender were the only clinical 
characteristics that differed significantly among the three 
study groups (Table 1); group I patients were younger than 
group III patients (p < 0.05) and more often female (p < 
0.01). Although group III patients received lower doses of 
quinidine than those given to group I or II patients, this 
difference did not reach statistical signifficance. 
Clinical arrhythmia characteristics (l’ables Ban 
spontaneous ventricular tachycardia cycle length was 316 5 
87 ms. Patients had a mean of 2.6 2 2.5 previous episodes of 
Table 2. Effects of Combination Therapy on Ventricular Refractoriness and Tachycardia Cycle 
Length in 46 Patients -_ 
Group I Group II Group III 
(n = 21) (n = 17) (n = 8) 
--- 
Baseline VT CL 298 + 81 
Posttreatment VT CL 
+ 324 + 62 
- I 432 2 70 ~ 279 k 73 I NS t -- 3 I4 It 6  
Baseline RVBRP 252 2 24 
1 t t 265 + 33 I 
e I___.^_- 234 t IY ? 
: 
Posttrcatment RVERP 316 + 28 316 f 24 286 lr ,3 I 
I--*-_.I 
1 t------J 
*P < 0.05 ‘fp < 0.001. AU values are xpressed in milliseconds. Groups are defined as in Table 1. RVERP = right 
ventricular etkctive refractory Period at a paced cycle length of 600 ms; VT CL = cycle length cf induced ventricular 
tachycardia. Note that 4 of the 50 patients did not undergo posttreatment etctrophysiologic study (see Results sectioi;). 
and 324 + 62 m. 
effective refractory period in 
sotalol. Sustaine 
these drugs. The induced ventricular tacbycardia cycle 
length was either 550 ms longer than at baseline (30 pa- 
tients), required cardioversion (15 patients) or was 60 to 
70 ms slower than at baseline and zould be terminated by 
pacing (4 patients, all taking ~roca~nam~de~ but with marked 
presyncope. 
Electroyhysiologic studies after drug ~o~~i~atio~~. 
Forty-six patients underwent electro Iologic study while 
receiving the drug combination. F :hers had baseline 
studies only, but were discharged ion combinat~o 
after frequent spontaneous episodes of ve 
ressed. In 21 patients, tat 
dered noninducible, whereas in17 patients. 
modified according to the preceding criteria. 
patients had tachycardia inducibility su 
37% had inducibilitjr modified, for a total e~ec~ro~hysiolog~c 
drug response rate of 83%. Forty-two patients were there- 
fore discharged on treatment with sotalol plus quinidine or 
procainamide. The remaining eight patients (17%) had no 
modification of induced ventricular tachycardia and were 
discharged on alternative therapy (amiodarone in seven 
patients, otalol in one). 
Drug &kcu on cardiuc ~r&ckkrzess (T&Be 2). Venttic- 
uiar refractoriness increased frsom the drug-free stake in all 
patients. The right ventricular refractory period 
increased to 316 + 28 ms in with non~~d~cib~e 
(group I) tac.Lycardia (p < 0. 16 * 24 ms in the 
group with modified group II (p < 0.001). Patients with 
r=0.50@<.02 
64 32 ms (a 26 
p < 0.02) (Fig. 1) as well as with the increase inventricular 
tachycardia cycle length 
suggesting the prolongat 
length was due at least in part to increased vent~c~~~ 
refractoriness. 
After treatment, ventricular tat ycardia ~yct: length in 
patients in whom tachycardia ndxibility was modifie 
(group II) increase to 432 2 70 ms, a mean increase of 
PO3 k 37 ms (k < 0. 1). In contrast. ventricular tacbycard~a 
ngth ii? patients in who ind~c~bi~ity was not m 
up Hlh) increased ky 35 2 103 to 314 
(p = NS). Amo og patients in v~rlho 
~~du~~‘b~e but was modified, the n 
quired to indtice vzntri 
the same in 11 patients, increas 
decreased ?y I in 2 patients. 
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E&cacy of qrrinidine versus procainamide in combination 
wit/l sot,dol. Thirteen patients were treated with procaina- 
mide and sotalol; tachycardia was rendered noninducible in 
five and inducibility was modified in four. Of 37 patients 
treated with quinidine and sotalol (33 with postdrug electro- 
physiologic study), tachycardir w,is rendered noninducible 
in I6 and inducibility was modified in 13 (p = NS). The 
posttreatment ffective refractory period was 317 2 24 in 
responders to soaalol plus quinidine versus 312 + 33 ms in 
responders t eated with sotalo! plus procainamide (p = NS). 
Drug do&g and serum concentrations. The mean dose of 
sotalol was 205 2 84 mglday. Predose sotalol concentration 
was measured in four patients reated successfully and was 
I.7 + 0.5 nglml. The mean dose of quinidine was 1,278 -C 
479 mg/day; the mean dose of procainamide was 2,393 +- 
1,423 &day. The sotalol and procainamide or quinidinc 
doses in the patients whose ventricular tachycardia induc- 
ibility was modified were similar lo those of patients whose 
tachycardia was rendered noninducible with the drug com- 
bination (Table I). 
CIiolcaE outcome. Forty-rwo patients, including all 38 
patients ingroups I and II were discharged ontreatment with 
sotalol in combination with quinidine or procainamide. No
patient died suddenly; all surviving patients were followed 
up for a minimum of I8 months (range I8 to 75). Four 
patients have had a recurrence of nonfatal sustained ventric- 
ular tachycardia, for an actuarial recurrence rate of 6 + 4% 
at 1 year and 6 -’ 4% and 11 ? 6% at 2 and j years, 
respectively (Fig. 2). 
One of these patients (who had noninducible tachycardia 
at electrophysi?logic during therapy) developed fatigue and 
diarrhea and stopped medications. Ventricular tachycardia 
recurred 2 days later and procainamide was substituted for 
the quinidine and the dose of sotalol was decreased. She has 
since (36 months later) had no further recurrence of ventric- 
ular tachycardia and is tolerating her medications well. A 
second patient (who had modified ventricular tachycardia 
inducibility) had a minimally symptomatic recurrence during 
Holter ECG monitoring, during which slow ventricular 
tachycardia was documented. The other two recurrences 
(both in group II patients) occurred after dose reduction of
sotalol because offatigue; one patient continues (20 months 
later) to take sotalol and procainamide and has had no 
further recurrence. Two patients died of heart failure. 
Among the patients discharged onalternative antiarrhyth- 
mic therapy (group III, n = 8) or in whom the sotalol-type Ia 
combination was permanently discontinued because ofside 
effects (n = 13) or arrhythmia recurrence (n= 2) 15 were 
treated with amiodarone, 6 with sotalol alone and I each 
with procainamide or qoinidine alone. They had an actuarial 
recurrence rate of sustained ventricular tachycardia (n = 1) 
or sudden death (n = 4) of 9 2 6% at I year (Fig. 2) and 
14 -’ 8% and 32 * 13% at 2 and 3 years, respectively 
Werence between the two survival curves, p = NS). 
Adverse dtllg effects. Procaiaamide was discontinued be- 
cause Of side effects in seven patients receiving combination 
Figure 2. Solid line, Actuarial freedom from recurrent ventricular 
tachycardia or sudden cardiac death (Kaplan-Meier method) in 42 
patients discharged on treatment with sotalol plus quinidine or 
procainamide. Actuarial recurrence rates (2 6 i: 4% at I 
year, 6 -C 4% at 2 years and I I 2 6% at 3 years. ioe, Freedom 
from, rccu;icnt ventricui.l- @....‘,*.,.. -, ru,.,,,&ia or suddeu citrdiac deaih in 23 
patients receiving other antiarrhythmic therapy: group III patients 
(nonmodified tachycardia at electrophysiologic study) and patients 
in whom sotalol plus a type Ia agent was discontinued because of 
side effects or tachycardia recurrence (see text). Actuarial recur- 
rence rates are 9 +- 6% at I year, 14 t 8% at 2 years and 32 5 13% 
at 3 years. The number of patients remaining in follow-up atvarious 
intervals is indicated beside each line for the two groups. 
therapy; two were subsequently reated with quinidine and 
had no ventricular tachycardia recurrence. Six patients 
receiving combination t erapy bad an adverse response to 
quinidine, necessitating its discontinuation; two of the six 
were subsequently reated with procainamide. Sotalol had 
adverse tfects in I I patients during combination therapy, 
predominantly fatigue and dyspnea; the :1ose was reduced in 
7 of these patients and sotalol was discontinued in 4. Thus, 
13 patients had combination therapy permanently discontin- 
ued. Seven of these were subsequently reated with amio- 
darone, four with sotalol alone and one patient each with 
quinidine and procainamide alone, 
There have been o instances ofsymptomatic proarrhyth- 
mia, unexplained syncope, an increase in the frequency of 
nonsustained ventricular tachycardia onHolter IECG moni- 
toring or any instances oftorsade de pointes. 
The principal findings of this study are that the combina- 
tion of low dose sotalol and quinidine or procainam: 12 is 
highly etfectivc in preventing recurrence UC sustained {en- 
tricular tachycardia. Suppression f tachycardia induci+lity 
or slowing of induced tachycardia at electrophysiclogic 
study are markers for a beneficial drug effect and the 
combination is relatively well tolerated without documented 
proarrhythmia during the period of observation. 
The use of serial electrophysiologic stndies to predict 
as not been well iavesti- 
that prolongs the action ponential ~~r~t~~~ in 
ac conduction (“class IC action’ 
recurrence of ventricular tachycardia and the theoretically 
and ex~e~me~ta~ly greater efficacy of prolongation f car- 
diac refractoriness to a greater extent han of conduction 
(12,14,15) prompted us to attempt to achieve maximal pro- 
longation of cardiac refractoriness with relatively ittle pro- 
longation of cardiac onduction. ~~~~i~i~e or procb’namide 
witk sotalol did result ira prolo 
riness greater than that usually seen witk 
alone. 
A considerable body of circu stantial evidence suggests 
that beta-blocker rapy may be highly effective as an 
adjunct to “antia bmic” therapy for patients with SIIS- 
tamed vetntricular tachycardia (26-30). Standard 
blockers may enhance the eficacy of~~~~idi~e in preventing 
in 4% and 4.5% of 
ed on treatment with sotalol alone 
ejection fraction <25%), our ~al.~e~ts were not 
~onind~c~ble a~hytbmias or modifi 
arial ventricular tachycar 
a, with only a 6% actu- 
nce rate after either I or 
compilations ofa~t~~~bytbmic 
cainamide to qdnidine or vice versa. 
concern over the poterrtial risk of pro 
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reF,~~n~~ti~:: tk p;;;dws m&xG prolongalion ofcardiac 
rebctohnes:; aild ir wtich the individual agents may be 
associated w&h dmg-induced anhythmias, 80 instaiices of
torsade de points5 j!zntricular tachycardia, unexplained syn- 
cope or symptoms possibly attributable to drug-induced 
arrhythmias were observed. The absence in this study of 
arrhythmias that may be associated with drug-induced QT 
prolongation highlights our incomplete understanding of the 
factors that lead to polymorphic ventricular tachycvdia in 
patients receiving drugs that prolong QT intervals. 
ts on cardiac refractoriness. The combination of
sot&l and quinidine or procainamide prolonged the right 
ventricular effective refractory period to a greater extent 
than has been reported for the individual drugs alone. 
Patients in group I (tachycardia rendered noninducible) had 
an increase in mean right ventricular effective refractory 
period to 318 f 28 ms, and those in group IL (inducibility 
modified) an increase to 316 f 24 ms. Fourteen of our 
patients underwent programmed stimulation while receiving 
procainamide alone, and mean right ventricular effective 
refractory period was 265 2 21.8 ms, significantly shorter 
than that in the same patients treated with sotalol plus 
procainamide or quinidine (304.6 Z!C 30.8 ms, p < 0.01). 
Similarly, quinidine alone (n = 4) produced less right ven- 
tricular effective refractory period prolongation, to255 + 
17 mr and cntalnl ala-m= In = 12) p&f& this v?d&jc tc . < -..u, ..a._ I_.-“- ..I_.._ \.a 
284.2 f 25.7 ms, significantly less than the combination f 
sotdol and a class Ia action drug (302 + 17.2 ms, p c 0.02) 
in the same patients. Similarly, others have observed drug- 
induced increases in right ventricular effective refractory 
period to approximately 260 to 290 ms in cohorts of patients 
treated with quinidine or procainamide alone (12,14), amio- 
dzone (38), sotalol(17,24,34) or propranolol p us quinidine 
or procainamide (27). 
Slowing of ventricular tachycardia may be caused by 
slowing of conduction or prolongation of refractoriness 
within the tachycardia circuit (39). For example, analysis of 
the elCect of procainamide onventricular tachycardia cycle 
length stiggcsts hat the drug has a preferential effect otl 
conduction slowing within the reentrant circuit (39). In the 
present study, however, the correlation between the right 
ventricular effective refractory period on treatment and the 
absolute and relative change in cycle length of ventricular 
tachycardia suggests that ventricular tachycardia slowing 
was predominantly or in part caused by an increase in 
ventricular refractoriness. 
Our findings are consistent with recent reports that pa- 
tients with tachycardia rendered noninducible atelectro- 
physiologic study have a greater prolongation f ventricular 
refractoriness than do those whose tachycardia. is still induc- 
ible (12-15) and corroborate theoretic and experimental 
suggestions that the balance between conduction slowing 
and refractoriness prolongation importantly influences the 
inducibility and stability of reentrant arrhythmias (40,41). 
Relatively greater refractoriness prolongation a d relatively 
less conduction slowing, as occurs with the combination f 
sot&4 and quinidine or procainamide, may lead to a smalle; 
excitable region (“excitable gap”) within tbe reentrant cir- 
cuit, thus inhibiting induction and promoting term~~atiol~ of 
tachycardia (15). 
In gl.Cnea pig papillary muscle, the sotslol 
bination causes a greater increase in effe 
period than that induced by either drug alone, modest 
increases inaction potential duration o greater than that 
induced by either d g alone and a smaller decrease in 
maximal velocity of se 0 of the action potential u 
(vmax) compared with that induced by quinidine alone (42). 
hysiolqic profile is consistent with the 
cls on r~f~acto~i~ess n patients. 
This was a nonrandomized albeit prospec- 
a novel drug combination. Not all patients 
underwent electrophysiologic studies \,ith sotaloi aione, 
although all had failed mo~otherapy with either procaina- 
mide or quiddine. There is relatively little information on 
the effcacy of sotalol alone in preventing ventricular tachy- 
cardia inducibility at the low doses used in this study. 
However, it is possible that in some patients tachycardia 
would have become noninducible during treatment with 
sotalol alone. Although patients whose tachycardia remains 
persistently inducible with either procainamide, quinidine or 
sotalol appear to have a high rate of ventricular tachycardia 
wmmvnrP nn c~thcwttrsmt Inno_.tmrn nral mnnnthm-amr thk .slll ._.._ _ I.. ‘w”“qL”.‘. ._.. 0 ._,“.. V.... “..Y..V.I..e...~J, S.‘.., 
uncontrolled study does not allow for comparison between 
the combination therapy and monotherapy with tbe same 
agents. 
The low doses of sotalol used in this study are likely to 
produce relatively greater beta-blockade effects t 
“class III” effects on ventricular myocardium (I I ,27). It is 
possible, therefore, that similar esults might have been 
achieved with combination therapy using beta-blockers such 
as propranolol, which have no class III effect. However, the 
small bur significant prolongation of effective refractory 
period by sotalol alone at doses imilar to those used in this 
study (43) and the marked prolongation f refractoriness we
observed suggest that he class PII action of sotalol is likely 
to have contributed to the success of the combination 
therapy independently of its beta-blocking effect. We did not 
measure the extent of QRS prolongation produced by the 
drug combination. The relative balance between prolonga- 
tion of refractoriness and conduction was inferred from the 
observed increases in right ventricular effective refractory 
period and the modest slowing of conduction to be expected 
at the modest concentrations of quinidine and procainamicie 
achieved. 
Conclusions. The combination f sotalol plus quinidine 01’ 
procainamide appears to be highly effective in preventing OI
modifying inducible ventricular tachycardia at electrophysi- 
ologic study. This drug combination appears effective for.the 
long-term suppression f recurrence of sustained ventricular 
tachycardia. Furthermore, the combination is associated 
with a marked prolongation f cardiac refractoriness, which 
may be associat.:d wit’h ciinicai benefit. Furtiher prospective 
sotalos plus 
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